Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peptide-drug co-assembly method for constructing reduction-responsive anticancer nanomedicine

A nanomedicine and co-assembly technology, applied in the field of nanomaterial technology and biomedical materials, can solve the problems of high toxicity and high synthesis cost, and achieve the effects of low biological toxicity, easy degradation and good biocompatibility

Active Publication Date: 2020-11-06
TIANJIN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to solve the problems existing in the prior art, the present invention provides a method for constructing reduction-responsive anti-cancer nano-drugs by co-assembling polypeptide-drugs, which solves the high synthesis cost of reduction-responsive anti-cancer nano-drugs of pure polypeptide materials in the prior art , the problem of high toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide-drug co-assembly method for constructing reduction-responsive anticancer nanomedicine
  • Peptide-drug co-assembly method for constructing reduction-responsive anticancer nanomedicine
  • Peptide-drug co-assembly method for constructing reduction-responsive anticancer nanomedicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] 1) Weigh the polypeptide and curcumin (CCM) and dissolve them in tetramethyl sulfoxide (DMSO), the concentration of the polypeptide is 1mg / 20μL DMSO, the concentration of CCM is 1mg / 30μL DMSO, according to the molar ratio of polypeptide:CCM=5:3 Mix the above two solutions, then add pH=5.5 phosphate buffer to dilute, the buffer concentration is 50mM, the final concentration of the diluted polypeptide is 0.5mg / mL, and the final concentration of curcumin is 0.3mg / mL;

[0035] 2) Incubating the mixed solution in step 1) at 16°C for 1 hour;

[0036] 3) After the incubation of the mixed solution in step 2) is completed, the mixed solution is centrifuged at 6000 rpm for 3 minutes to remove the precipitate, and the supernatant is taken to obtain the nanomedicine.

Embodiment 2

[0038] 1) Weigh the polypeptide and curcumin (CCM) and dissolve them in ethanol respectively, the concentration of the polypeptide is 1 mg / 5 μL ethanol, the concentration of CCM is 1 mg / 100 μL ethanol, mix the above two solutions according to the molar ratio of polypeptide:CCM=5:1, Then add citrate buffer with pH=6.5 for dilution, the buffer concentration is 30mM, the final concentration of the diluted polypeptide is 0.3mg / mL, and the final concentration of curcumin is 0.06mg / mL;

[0039] 2) Incubating the mixed solution in step 1) at 30° C. for 1 hour;

[0040]3) After the incubation of the mixed solution in step 2) is completed, the mixed solution is centrifuged at 4000 rpm for 10 minutes to remove the precipitate, and the supernatant is taken to obtain the nanomedicine.

Embodiment 3

[0042] 1) Weigh the polypeptide and 10-hydroxycamptothecin (HCPT) and dissolve them in methanol respectively. The concentration of the polypeptide is 1mg / 10μL methanol, and the concentration of CCM is 1mg / 60μL methanol. The two solutions were then diluted with a citrate buffer solution of pH=5, the buffer solution concentration was 45mM, the final concentration of the diluted polypeptide was 0.8mg / mL, and the final concentration of curcumin was 0.8mg / mL;

[0043] 2) Incubating the mixed solution in step 1) at 25°C for 2.5 hours;

[0044] 3) After the incubation of the mixed solution in step 2) is completed, the mixed solution is centrifuged at 5000 rpm for 8 minutes to remove the precipitate, and the supernatant is taken to obtain the nanomedicine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
diameteraaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses a method for constructing a reduction response type anticancer nanometer medicine by polypeptide-medicine co-assembling. Pure polypeptide which contains a disulfide bond is designed, and a mutual function between the pure polypeptide and an anticancer medicine is used for realizing polypeptide and medicine co-assembling to obtain the anticancer nanometer medicine. The polypeptide used in the method only consists of amino acid, and other non-peptide groups do not need to be modified so as to be simple in synthesis. The adopted polypeptide has good biocompatibility and low biotoxicity and can be easily degraded in vivo. The adopted polypeptide can sensitively respond to GSH (glutathione), medicines can be quickly released on a tumor position, and medicine use efficiency is improved. According to the nanometer medicine, an anti-cancer function can be stably performed in a living body, and the nanometer medicine does not generate an obvious toxic and side functionson healthy tissues.

Description

technical field [0001] The invention belongs to the technical field of nanomaterials and the field of biomedical materials, and relates to a preparation method of a reduction-responsive anticancer nanometer drug. Background technique [0002] Cancer is a disease that seriously threatens human health. Judging from the achievements of the medical field, the main method of cancer treatment is chemotherapy. Therapeutic effect, but at the same time it will have serious toxic side effects on normal cells of the human body. Anti-cancer nano-drugs use biocompatible materials to load drugs, and the obtained nano-scale drugs can be taken up by tumor cells through the high permeability and retention effect (EPR effect) of solid tumors, thus reducing the release of drugs in normal cells chance, weakening the damage to normal tissue. [0003] Tumor cells are vigorously active, proliferate frequently, and require a large amount of oxygen and nutrients to support. The rapid metabolism ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/107A61K47/42A61K31/12A61K31/4745A61K31/704A61K31/337A61P35/00
CPCA61K9/1075A61K31/12A61K31/337A61K31/4745A61K31/704A61K47/42A61P35/00
Inventor 王梦凡齐崴代叶梅苏荣欣
Owner TIANJIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com